Evidence map›Paper›PMID 40656111›Full record

ReviewNeuroscience applied2024

Natural killer (NK) cells in bipolar disorders.

Ryad Tamouza, Marion Leboyer, Vincent Vieillard

Abstract readReview
In one paragraph

Review in Neuroscience applied, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ryad TamouzaUniversité Paris-Est Créteil (UPEC), INSERM, IMRB, Translational Neuropsychiatry, AP-HP, Hôpitaux Universitaires Henri Mondor, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT, DMU IMPACT), Fondation FondaMental, F-94010, Créteil, France.
Marion LeboyerUniversité Paris-Est Créteil (UPEC), INSERM, IMRB, Translational Neuropsychiatry, AP-HP, Hôpitaux Universitaires Henri Mondor, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT, DMU IMPACT), Fondation FondaMental, F-94010, Créteil, France.
Vincent VieillardSorbonne Université, Inserm U1135, CNRS EMR 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), F-75013, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroinflammation and peripheral immune dysregulations, affecting both innate and adaptive immune responses, have repeatedly been demonstrated in bipolar disorder (BD). Given the increased susceptibility to infections, the chronic inflammation and autoimmune processes, abnormalities affecting the natural killer (NK) cells compartment are likely to play an important role in the pathophysiology of BD. We here address this question by describing current knowledge regarding phenotypic and functional characteristics of NK cells in BD in the context of well-established environmental risk factors as well as crosstalk between NK cells and other immune cells. Patients with BD show a permanent activation of NK cells along with a specific expansion of a cell subset, called "adaptive NK cells", usually associated with several viral infections. We thus discuss the putative role of non-resolved infectious events in BD, possibly arising from suboptimal, genetically determined, anti-infectious responses or from yet to be identified other pathophysiological processes. The observed deregulation of NK cells in patients with BD may contribute to impaired immune functions, heightened inflammation, neuro-immune damage as well as cognitive decline and resistance to treatment, thus stressing the need of a deeper analysis of these immune cells in BD.

Indexed as

Bipolar disorderInfectionsInflammationNatural killer cells

Identifiers

PMID40656111
PMCPMC12244116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.